Health Care [ 2/12 ] | Biotechnology [ 3/73 ]
NASDAQ | Common Stock
uniQureN. V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding.
Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease.
The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease.
It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQureN. V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 29, 25 | -0.69 Increased by +40.52% | -0.89 Increased by +22.47% |
| Jun 18, 25 | -0.73 Increased by +46.49% | -0.89 Increased by +17.88% |
| Feb 24, 25 | -1.44 Increased by +5.78% | -0.52 Decreased by -178.82% |
| Nov 5, 24 | -0.91 Increased by +51.60% | -1.02 Increased by +10.78% |
| Aug 1, 24 | -1.16 Increased by +19.44% | -1.25 Increased by +7.20% |
| May 7, 24 | -1.36 Increased by +16.56% | -1.28 Decreased by -6.25% |
| Feb 28, 24 | -1.53 Decreased by -1.12 K% | -1.46 Decreased by -4.79% |
| Nov 7, 23 | -1.88 Decreased by -84.31% | -0.85 Decreased by -121.18% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 5.26 M Decreased by -52.71% | -37.72 M Increased by +33.00% | Decreased by -716.82% Decreased by -41.66% |
| Mar 31, 25 | 1.57 M Decreased by -81.53% | -43.64 M Increased by +33.50% | Decreased by -2.78 K% Decreased by -260.09% |
| Dec 31, 24 | 5.22 M Decreased by -21.95% | -73.26 M Decreased by -0.08% | Decreased by -1.40 K% Decreased by -28.21% |
| Sep 30, 24 | 2.29 M Increased by +62.54% | -44.38 M Increased by +50.45% | Decreased by -1.94 K% Increased by +69.52% |
| Jun 30, 24 | 11.13 M Increased by +359.37% | -56.30 M Increased by +17.78% | Decreased by -506.01% Increased by +82.10% |
| Mar 31, 24 | 8.48 M Increased by +59.34% | -65.62 M Increased by +15.03% | Decreased by -773.34% Increased by +46.68% |
| Dec 31, 23 | 6.69 M Decreased by -93.49% | -73.21 M Decreased by -1.18 K% | Decreased by -1.09 K% Decreased by -16.62 K% |
| Sep 30, 23 | 1.41 M Decreased by -2.90% | -89.57 M Decreased by -87.16% | Decreased by -6.37 K% Decreased by -92.75% |